Why the study?
Does compound 4i prevent cardiac injury in rats with isoproterenol-induced myocardial infarction?
Does compound 4i prevent cardiac injury in rats with isoproterenol-induced myocardial infarction?
A novel thiazole-pyrazolone hybrid, compound 4i, demonstrated potent ACE inhibition and cardioprotective effects against isoproterenol-induced myocardial infarction in a rat model.
Answers are grounded in this paper and cite their sources.
Thiazole-pyrazolone hybrids show ACE inhibition in animal models; this Level 5 finding leaves open clinical translation.
A facile synthesis of a group of novel thiazole-pyrazolone hybrids and their investigation for angiotensin-converting enzyme (ACE) inhibition are reported in this study. These compounds were synthesized using a well-known approach, based on the condensation of ethyl acetoacetate with thiazolylhydrazines, and characterized by various spectroscopic and analytical techniques. The entire set of compounds displayed a moderate-to-excellent inhibitory activity against ACE. In particular, compound 4i was found to be the most potent ACE inhibitor and was further studied for cardioprotective effects against isoproterenol (ISO)-induced myocardial infarction (MI) in rats. Compound 4i improved the cardiac function and prevented cardiac injury induced by ISO in Sprague Dawley rats. The levels of oxidative stress and proinflammatory cytokines were also restored to near normal by 4i as compared with the ISO group. In the Western blot analysis, compound 4i prevented mitochondrial apoptosis after MI by downregulating the expression of cleaved caspase-3 and Bax, with the upregulation of Bcl-2, as compared with the ISO group.
No takes yet. Share an insight, caveat, or question.
Su et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: